Propanc Biopharma established a four-year joint research partnership with the Jaén University in Spain to expand the company’s product pipeline.
Propanc Biopharma (OTCQB:PPCB) established a four-year joint research partnership with the Jaén University in Spain to expand the company’s product pipeline.
As quoted in the press release:
The primary objective of the partnership is to expand Propanc Biopharma’s product pipeline, by discovering new compounds based on the mode of action of naturally derived proenzymes, trypsinogen and chymotrypsinogen, which are the key active ingredients in the Company’s lead product, PRP.
The newly established partnership involves the recruitment and co-financing of a doctoral student for a period of up to 4 years, providing 50% of the total cost of the contract, including training of research staff and enrolment in the doctoral program. Dr Macarena Perán Quesada, lecturer at Jaén University, scientific advisor to Propanc Biopharma, will lead the joint research program.
“I am very pleased to announce the execution of the next phase for our POP1 research program, as we look to expand our product pipeline in the future,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “Based on years of collaboration and a close, professional relationship with Dr Perán, we have a great deal of confidence in her scientific expertise and understanding of the mechanistic effects of proenzymes as a new therapeutic approach to the treatment and prevention of metastatic cancer. We look forward to the opportunity of identifying and developing new follow on compounds to our lead product, PRP.”